JEREMIAS ABUEME: Open Payments
NPI 1891790960 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$553 in 33 payments from 8 companies in 2025. Trend: 2023 $1,022 · 2024 $951 · 2025 $553
Food & beverage: $553
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 15 | $184 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $107 |
| GlaxoSmithKline, LLC. | 5 | $99 |
| AstraZeneca Pharmaceuticals LP | 3 | $56 |
| Novo Nordisk Inc | 2 | $53 |
| Lilly USA, LLC | 1 | $26 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $15 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $14 |
Products named: OTEZLA, JARDIANCE, TRELEGY ELLIPTA, Ozempic, REPATHA, MOUNJARO, KRYSTEXXA, BREZTRI.
Industry payments across TX — which companies pay providers there.
